• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALT alert in real time by email

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH

    Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises

    GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing clinical development of pemvidutide including the planned Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH). He succeeds Scott Harris, M.D., who earlier this year informed the Company of his plans to retire from the position. Dr. Harris will remain with the Company as a Senior Strategic Advisor until February 2026.

    "We are thrilled to welcome Christophe to the team at this crucial juncture in Altimmune's evolution," said Vipin K. Garg, Ph.D., President and CEO of Altimmune. "He brings a wealth of experience across mid- and late-stage clinical development, regulatory approvals and commercial launches that will be invaluable as we continue to advance pemvidutide and work toward our mission of establishing a new standard of care in the treatment of hepato-metabolic disorders. On behalf of the executive team and Board of Directors, I would also like to thank Scott for his instrumental contributions over the last six years. His oversight of the pemvidutide program through multiple INDs and clinical trials has positioned us well as we prepare to enter Phase 3 development in MASH."

    Dr. Arbet-Engels added, "I am proud to join the talented leadership team at Altimmune and excited to lead the development of a therapy as promising as pemvidutide. The data generated to date reinforces the highly differentiated profile of pemvidutide as well as its category-leading potential in MASH. With upcoming 48 week data from the IMPACT trial in MASH, as well as the ongoing Phase 2 trials in Alcohol Use Disorder and Alcohol-associated Liver Disease, pemvidutide presents an exciting opportunity to disrupt the treatment paradigm in three highly prevalent indications and potentially address multiple significant unmet medical needs. I look forward to working closely with Vipin and the rest of the team as we advance to the End-of-Phase 2 meeting with the FDA and continue working toward the initiation of the Phase 3 trial in MASH."

    Dr. Arbet-Engels joins Altimmune from X4 Pharmaceuticals (NASDAQ: XFOR), where he served as Chief Medical Officer since 2023. While at X4, he contributed extensively to the successful regulatory process for Xolremdi (mavorixafor), which was approved in 2024 for WHIM Syndrome, and led late-stage clinical programs for mavorixafor in Chronic Neutropenia. Previously, he was Chief Medical Officer at Neurogastrx, Millendo Therapeutics, and Poxel Pharmaceuticals, where he led the clinical development and approval in Japan of Twymeeg for diabetes. Earlier in his career, he held several senior-level medical and clinical positions including at Biogen, Boehringer Ingelheim Pharmaceuticals, Hoffmann-La Roche, Merck Research Laboratories, Aventis Pharmaceuticals, and Ligand Pharmaceuticals, where he led clinical development and registration, launch and lifecycle management efforts for a variety of products including LANTUS® and JARDIANCE®. Prior to his career in industry, Dr. Arbet-Engels served in educational roles at The Salk Institute for Biological Studies, University of Paris VI, and the Assistance Publique, Hospitals of Paris, and he currently serves as a Member of the Board of Tutors in Biochemical Sciences at Harvard University. Dr. Arbet-Engels received his MD and PhD in internal medicine and endocrinology/metabolism from the University of Paris, France, and completed his MBA at Rutgers University. He completed a postdoctoral fellowship in the Department of Medicine, Division of Endocrinology and Metabolism at the University of California, San Diego, and residencies in Endocrinology and Internal Medicine at Military Hospital Bégin, Paris and Assistance Publique, Hospitals of Paris, respectively.

    Inducement Grant

    In connection with being named as Chief Medical Officer, Dr. Arbet-Engels will receive, in the aggregate, options to purchase 450,000 shares of Altimmune's common stock, and 150,000 restricted stock units ("RSUs"). The options will have an exercise price equal to the closing price of Altimmune's common stock on October 1, 2025 (the "Grant Date"). Based on the closing price of Altimmune's common stock on October 1, 2025, Altimmune would issue approximately 347,436 options as inducement awards under its 2018 Inducement Grant Plan, and the balance as incentive stock options under its 2017 Omnibus Incentive Plan. The final allocation of options between the 2018 Inducement Grant Plan and 2017 Omnibus Plan are subject to adjustment based on the closing price of Altimmune's common stock on the Grant Date. One-fourth of the shares underlying the options will vest on the one-year anniversary of the Grant Date and thereafter 1/36th of the shares underlying the options will vest monthly, such that the shares underlying the options will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to Dr. Arbet-Engels continued employment with Altimmune on such vesting dates.

    One-fourth of the RSUs will vest on the one-year anniversary of the Grant Date and thereafter the RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to Dr. Arbet-Engel's continued employment with Altimmune on such vesting dates. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

    About Altimmune

    Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.

    Forward-Looking Statements

    Any statements made in this press release related to the development or commercialization of pemvidutide, an investigational product candidate, and other business, regulatory and financial matters including without limitation, the timing of key milestones for the Company's clinical assets, future plans or expectations for pemvidutide for the treatment of MASH, AUD, ALD and obesity, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements, or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K, quarterly report on Form 10-Q and the Company's other filings with the SEC, which are available at www.sec.gov.

    Follow @Altimmune, Inc. on LinkedIn

    Follow @AltimmuneInc on X

    Investor Contact:

    Lee Roth

    Burns McClellan

    Phone: 646-382-3403

    [email protected]



    Primary Logo

    Get the next $ALT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALT
    $XFOR

    CompanyDatePrice TargetRatingAnalyst
    Altimmune Inc.
    $ALT
    7/10/2025$1.00Sell
    Goldman
    Altimmune Inc.
    $ALT
    2/28/2025Mkt Perform
    William Blair
    Altimmune Inc.
    $ALT
    1/8/2025$18.00Buy
    Stifel
    Altimmune Inc.
    $ALT
    11/12/2024$26.00Buy
    UBS
    Altimmune Inc.
    $ALT
    4/29/2024Buy → Neutral
    Guggenheim
    Altimmune Inc.
    $ALT
    1/24/2024$13.00Neutral
    Goldman
    X4 Pharmaceuticals Inc.
    $XFOR
    12/12/2023$3.00 → $1.00Buy → Neutral
    B. Riley Securities
    X4 Pharmaceuticals Inc.
    $XFOR
    8/30/2023$3.00Buy
    B. Riley Securities
    More analyst ratings

    $ALT
    $XFOR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALT
    $XFOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Baldry Mark bought $2,561 worth of shares (1,032 units at $2.48), increasing direct ownership by 4% to 25,337 units (SEC Form 4)

    4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

    5/20/25 4:51:03 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sohn Catherine A. bought $5,784 worth of shares (1,000 units at $5.78) (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/18/25 4:15:22 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Weaver Gregory L bought $51,996 worth of shares (10,000 units at $5.20) (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/14/25 7:27:34 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    $XFOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altimmune to Participate in Two Upcoming Investor Conferences

    GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences: Stifel 2025 Virtual Cardiometabolic ForumTuesday, September 30, 2025Fireside Chat at 10:30 a.m. Eastern Time H.C. Wainwright Liver Disease Virtual ConferenceTuesday, October 21, 2025Fireside Chat at 7:00 a.m. Eastern Time The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

    9/23/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

    Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in addition to his current role as President Dr. Adam Craig, Executive Chairman, to have oversight over clinical development BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced a strategic restructuring designed to sharpen operational focus and align resources with the Company's long‑term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and se

    9/17/25 7:00:00 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALT
    $XFOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Altimmune with a new price target

    Goldman resumed coverage of Altimmune with a rating of Sell and set a new price target of $1.00

    7/10/25 8:47:17 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Altimmune

    William Blair initiated coverage of Altimmune with a rating of Mkt Perform

    2/28/25 7:17:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Altimmune with a new price target

    Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00

    1/8/25 7:32:53 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    $XFOR
    SEC Filings

    View All

    Altimmune Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Altimmune, Inc. (0001326190) (Filer)

    9/25/25 4:07:15 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by X4 Pharmaceuticals Inc.

    424B3 - X4 Pharmaceuticals, Inc (0001501697) (Filer)

    9/18/25 4:19:13 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by X4 Pharmaceuticals Inc.

    EFFECT - X4 Pharmaceuticals, Inc (0001501697) (Filer)

    9/18/25 12:15:16 AM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALT
    $XFOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sohn Catherine A.

    4 - Altimmune, Inc. (0001326190) (Issuer)

    9/29/25 4:21:00 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Durso Jerome Benedict

    4 - Altimmune, Inc. (0001326190) (Issuer)

    9/29/25 4:20:03 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lawver Teri L

    4 - Altimmune, Inc. (0001326190) (Issuer)

    9/29/25 4:19:09 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    $XFOR
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

    GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises

    9/15/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sitryx appoints Adam Mostafa as Chief Financial Officer

    Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial

    9/8/25 7:00:00 AM ET
    $ABP
    $CPIX
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ALT
    $XFOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

    SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

    11/14/24 11:58:56 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc.

    SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

    11/12/24 5:59:35 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc.

    SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

    11/4/24 2:15:54 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALT
    $XFOR
    Financials

    Live finance-specific insights

    View All

    Altimmune Announces Second Quarter 2025 Financial Results and Business Update

    Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis End-of-Phase 2 Meeting with FDA expected in Q4 2025 Cash, cash equivalents and short-term investments of $183.1 million as of June 30, 2025 Webcast to be held today, August 12, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:A

    8/12/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

    GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor R

    8/5/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

    First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2

    6/26/25 7:00:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care